Abiomed, part of Johnson & Johnson MedTech, announced that novel data from seven research studies focused on optimizing outcomes for patients receiving Impella-supported high-risk percutaneous coronary intervention (HRPCI) will be presented at the 35th Transcatheter Cardiovascular Therapeutics (TCT) annual scientific symposium taking place in San Francisco between Oct. 24 - 26. As part of an academic collaboration coordinated by the Cardiovascular Research Foundation (CRF)22, researchers conducted new analyses of data from the prospective, multicenter PROTECT III study, which includes the most robust contemporary data set of 1,237 Impella-supported HRPCI patients treated at 46 sites in the U.S. between March 2017- March 2020.

The seven studies include an analysis of the characteristics of PROTECT III patients that demonstrates how physicians are distinguishing which patients are high-risk and appropriate for Impella- supported HRPCI procedures. The data shows that 82.5% of patients have features in all three high-risk domains: comorbidities, complex coronary anatomy and adverse hemodynamics. It also demonstrates that 99.6% of patients have risk factors from two or more of the high-risk domains.

Additional Impella HRPCI abstracts being presented on Oct. 26 include (in order of presentation timing): TCT 143: Prognostic Implications of Anemia in Impella-Supported HRPCI: Insights From the cVAD PROTECT III Study; TCT 145: relationship between Preprocedural Blood Pressure and Outcomes in Patients Undergoing Impella-Supported High-Risk PCI - Insights From the cV AD PROTECT III Study; T CT 214: Right Ventricular Function in Patients Undergoing Impell-Assisted High-Risk Percutaneous Coronary Intervention: Insights From the c VAD PROTECT III Study; tCT 241: Clinical Characteristics and Outcomes of Impella-Supported High -Risk PCI in Patients Turned Down for Coronary Artery Bypass Graft Surgery: Insights from the cVAD PROTECT II Study; TCT 219: Performance of Existing Risk Models in Impella-Supported High the High-Risk Percutaneously Coronary Intervention; TCT 240: A-SMART-EF: A Novel Score to Predict Mortality in Patients Undergoing ImPElla-Assisted Percutaneous Coronary Intervention.